公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma | Sangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG ; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A. | Journal of Hepatology | 223 | 207 | |
2010 | Eastern asian expert panel opinion: Designing clinical trials of molecular targeted therapy for hepatocellular carcinoma | Yeo W.; PEI-JER CHEN ; Furuse J.; Han K.-H.; CHIUN HSU ; Lim H.-Y.; Moon H.; Qin S.; Yeoh E.-M.; Ye S.-L. | BMC Cancer | 4 | 4 | |
2017 | Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study | Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG ; Kihara K.; Sato A.; Tanaka M. | ESMO Open | 10 | 40 | |
2010 | Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: Experts'opinion | PEI-JER CHEN ; Furuse J.; Han K.-H.; CHIUN HSU ; Lim H.-Y.; Moon H.; Qin S.; Ye S.-L.; Yeoh E.-M.; Yeo W. | Liver International | 37 | 34 | |
2010 | Liver cancer working group report | Kudo M.; Han K.H.; Kokudo N.; ANN-LII CHENG ; Choi B.I.; Furuse J.; Izumi N.; Park J.-W.; Poon R.T.; Sakamoto M. | Japanese Journal of Clinical Oncology | 54 | 53 | |
2018 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYnote-061): a randomised, open-label, controlled, phase 3 trial | Shitara K.; ?zg?ro?lu M.; Bang Y.-J.; Di Bartolomeo M.; Mandal? M.; Ryu M.-H.; Fornaro L.; Olesi?ski T.; Caglevic C.; Chung H.C.; Muro K.; Goekkurt E.; Mansoor W.; McDermott R.S.; Shacham-Shmueli E.; Chen X.; Mayo C.; Kang S.P.; Ohtsu A.; Fuchs C.S.; Lerzo G.; O'Connor J.M.; Mendez G.A.; Lynam J.; Tebbutt N.; Wong M.; Strickland A.; Karapetis C.; Goldstein D.; Vasey P.; Van Laethem J.-L.; Van Cutsem E.; Berry S.; Vincent M.; Muller B.; Rey F.; Zambrano A.; Guerra J.; Krogh M.; Baeksgaard L.; Yilmaz M.; Elme A.; Magi A.; Auvinen P.; Alanko T.; Moehler M.; Kunzmann V.; Seufferlein T.; Thuss-Patience P.; Goekkurt E.; Hoehler T.; Haag G.; Al-Batran S.-E.; Castro H.; Lopez K.; Aguilar Vasquez M.; Sandoval M.; Lam K.O.; Cuffe S.; Kelly C.; Geva R.; Shacham-Shmueli E.; Hubert A.; Beny A.; Brenner B.; Giuseppe A.; Falcone A.; Maiello E.; Passalacqua R.; Montesarchio V.; Hara H.; Chin K.; Nishina T.; Komatsu Y.; Machida N.; Hironaka S.; Satoh T.; Tamura T.; Sugimoto N.; Cho H.; Omuro Y.; Kato K.; Goto M.; Hyodo I.; Yoshida K.; Baba H.; Esaki T.; Furuse J.; Wan Mohammed W.Z.; Hernandez Hernandez C.; Casas Garcia J.; Dominguez Andrade A.; Clarke K.; Hjortland G.; Glenjen N.; Kubiatowski T.; Jacek J.; Wojtukiewicz M.; Lazarev S.; Lancukhay Y.; Afanasayev S.; Moiseyenko V.; Kostorov V.; Protsenko S.; Shirinkin V.; Sakaeva D.; Fadeeva N.; Yong W.P.; Ng C.H.M.; Robertson B.; Rapaport B.; Cohen G.; Dreosti L.; Ruff P.; Jacobs C.; Landers G.; Szpak W.; Roh S.-Y.; Lee J.; Kim Y.H.; Bang Y.-J.; Chung H.C.; Ryu M.-H.; Alsina Maqueda M.; Longo Munoz F.; Cervantes Aguilar A.; Aranda Aguilar E.; Garcia Alfonso P.; Rivera F.; Feliu Batle J.; Pazo Cid R.; KUN-HUEI YEH ; Chen J.-S.; Chao Y.; Yen C.-J.; ?zg?ro?lu M.; Kara O.; Yalcin S.; Hochhauser D.; Chau I.; Benson A.; Shankaran V.; Shaib W.; Philip P.; Sharma V.; Siegel R.; Sun W.; Wainberg Z.; George B.; Bullock A.; Myrick S.; Faruol J.; Siegel R.; Larson T.; Becerra C.; Ratnam S.; Richards D.A.; Riche S.L.; KEYnote-061 investigators | The Lancet | 943 | 844 | |
2020 | A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies | Yamamoto N.; Ryoo B.-Y.; Keam B.; Kudo M.; CHIA-CHI LIN ; Kunieda F.; Ball H.A.; Moran D.; Komatsu K.; Takeda K.; Fukuda M.; Furuse J.; Morita S.; Doi T. | Investigational New Drugs | 15 | 14 | |
2013 | Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study | Ueno H.; Ioka T.; Ikeda M.; Ohkawa S.; Yanagimoto H.; Boku N.; Fukutomi A.; Sugimori K.; Baba H.; Yamao K.; Shimamura T.; Sho M.; Kitano M.; ANN-LII CHENG ; Mizumoto K.; Chen J.-S.; Furuse J.; Funakoshi A.; Hatori T.; Yamaguchi T.; Egawa S.; Sato A.; Ohashi Y.; Okusaka T.; Tanaka M.; 鄭安理 | Journal of Clinical Oncology | 508 | 467 | |
2017 | Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer | Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG ; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group | Journal of Cancer Research and Clinical Oncology | 25 | 18 | |